HC Wainwright Reaffirms “Buy” Rating for Inventiva (NASDAQ:IVA)

Inventiva (NASDAQ:IVA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $13.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 343.53% from the stock’s previous close.

Separately, TD Cowen began coverage on Inventiva in a research note on Friday, February 21st. They issued a “buy” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.60.

Inventiva Stock Performance

IVA opened at $2.93 on Friday. The firm’s fifty day moving average is $2.70 and its 200 day moving average is $2.48. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $3.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.